20 results about "Gastrointestinal absorption" patented technology

The invention belongs to the technical field of medicines, and discloses a betahistine mesylate oral soluble film agent for treating meniere disease, meniere syndrome and vertigo symptoms caused by vertigo and a preparation process thereof, the preparation process comprises the following steps: (1) adding betahistine mesylate into purified water; (2) adding glycerol, citric acid, sucralose, liquid orange-flavored essence and sunset yellow into the raw material medicine solution; (3) taking HPMC-E15, dispersing the HPMC-E15 in purified water, and adding HPC-LXF for thickening; (4) adding the medicine-containing solution into the blank glue solution; (5) degassing; (6) coating; and (7) cutting and packaging. Compared with a common tablet, the oral soluble film disclosed by the invention has a higher release rate, and can enter a body through a sublingual vein way in addition to a conventional gastrointestinal tract absorption way after being dissolved in an oral cavity, so that the bioavailability is increased; under the condition of stability acceleration, the compound has a better impurity level, and the preparation process is simple to operate, high in repeatability and suitable for industrial large-scale production.

The application relates to the technical field of biological medicine, and particularly provides a pharmaceutical composition containing a peptide drug active molecule and an application thereof. The pharmaceutical composition comprises a peptide drug active molecule and a drug delivery molecule, and the weight ratio of the peptide drug active molecule to the drug delivery molecule is 1:(1-500); the drug delivery molecule is selected from a structure as shown in formula (I) or a pharmaceutically acceptable salt thereof. The application provides an application of the pharmaceutical composition in preparing an oral dosage form drug. The peptide drug active molecule is significantly improved in stability and permeability in a gastrointestinal fluid by being compounded with the drug delivery molecule, so that gastrointestinal absorption of the peptide drug active molecule is increased and oral bioavailability of the peptide drug active molecule is improved.

The present invention relates to an orally administrable nutraceutical composition comprising omega- 3 fatty acids, at least one plant-derived extract exhibiting hypolipidemic activity, and an antioxidant. Hie composition is formulated as a nanoemulsion to enhance bioavailability, improve gastrointestinal absorption, and increase the therapeutic efficacy of the active compounds. The synergi stic interaction between omega- 3 fatty-7 acids and the bioactive component of plant extract promotes significant reduction in blood plasma triglyceride levels, supporting cardiovascular health. Hie formulation demonstrates improved pharmacokinetic parameters, including enhanced systemic exposure of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), compared to commercially available omega- 3 supplements, including increased bioavailability under both fasted and fed conditions. This invention offers a novel strategy for enhancing the therapeutic efficacy of omega- 3 fatty acids in the management of cardiovascular diseases.

The application discloses methyl phenolic compounds, a preparation method and application thereof. Six new methyl phenolic compounds are separated from the skin of eleocharis tuberosa, and the compounds all show good inhibitory activity on alpha-glucosidase, and are stronger than the clinical first-line drug acarbose. The inhibitory activity of compound 3 is the best, enzyme kinetics research shows that the compound 3 plays a role as a reversible mixed inhibitor, ADME predicts that the compound 3 has good drug properties, including high gastrointestinal absorption and no CYP450 enzyme inhibition. The cytotoxicity experiment shows that the six compounds have no obvious growth inhibition on human embryonic kidney cells HEK293 at a concentration of 100 muM, and have good safety. The compounds can be combined with a pharmaceutically acceptable carrier to form a pharmaceutical composition, and are used for preparing a health care product for reducing blood sugar or a drug for treating diabetes. The preparation method is simple, easy to operate, suitable for industrial production, and is helpful to the high-value reuse of the skin of eleocharis tuberosa.

Long-acting glucagon like peptide 1 receptor agonists (GLP-1r agonists) reduce and inhibit pathological processes that give rise to long-term neurological impairment. A biotinylated and / or lipidated GLP-1r agonist analogs with enhanced enzymatic stability needed for gastrointestinal absorption, improved bioavailability and pharmacokinetics are described. In preferred embodiments, the GLP-1r agonist analogs have the amino acid sequence of any one of SEQ ID NOs: 9-35. The compositions are typically administered via oral or parenteral routes. The compositions are particularly suited for treating, alleviating, and / or preventing one or more neurological diseases or disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD). Methods of treating a human subject having AD or PD or at risk of AD or PD are provided.

The application belongs to the technical field of plant genetic engineering, and particularly relates to a millet gene Seita.8G189900 and Seita.8G190200 application in controlling prolamine quality. The nucleotide sequence of the millet gene Seita.8G189900 is shown as SEQ ID NO. 1, and the nucleotide sequence of the millet gene Seita.8G190200 is shown as SEQ ID NO. 2. The application proves two genes that can down-regulate the content of prolamine in millet, and the prolamine content of millet can be reduced by reducing the expression level of the genes. Knocking out the two genes can not only down-regulate the content of prolamine, but also up-regulate the content of amino acid, increase the nutritional value of millet, and be more beneficial to gastrointestinal absorption and digestion, thereby providing a new gene resource for protein quality improvement.

The invention relates to the technical field of nutritious sports food, and discloses cashew nut and sea cucumber peptide exercise recovery powder and a method, the cashew nut and sea cucumber peptide exercise recovery powder comprises the following components by mass: 40%-55% of a composite peptide composition, 25%-35% of a rapid energy supply matrix, 5%-10% of an anti-inflammatory active component, and 10%-15% of a synergistic auxiliary agent, the composite peptide composition is formed by compounding a cashew nut extract and sea cucumber peptide according to a mass ratio of (4-6): (3-5), the molecular weight distribution of the cashew nut extract is 200-800Da, the purity of the cashew nut extract is greater than or equal to 92%, the molecular weight distribution of the sea cucumber peptide is 300-1000Da, the purity of the sea cucumber peptide is greater than or equal to 90%, the rapid energy supply matrix is formed by compounding maltodextrin and fructo-oligosaccharide according to a mass ratio of (3-4): 1, and the anti-inflammatory active component comprises curcumin microcapsules and resveratrol. Through the specific compounding design of the cashew nut extract and the sea cucumber peptide, in combination with precise molecular weight control, advantage complementation of amino acid composition is achieved, and the gastrointestinal tract absorption efficiency of nutritional ingredients is remarkably improved in cooperation with a targeted slow release technology of curcumin microcapsules.

The invention discloses a ginsenoside glutathione liposome as well as a preparation method and application thereof, and particularly provides the ginsenoside glutathione liposome which is characterized in that raw materials of the ginsenoside glutathione liposome comprise the following components in percentage by mass: 15%-20% of glutathione, 5%-10% of ginsenoside, 35%-40% of sunflower lecithin and 35%-40% of maltodextrin. The mass fraction refers to the mass percentage of each component in the raw materials. The ginsenoside glutathione liposome provided by the invention is stable in property, controllable in particle size, high in drug encapsulation efficiency, good in drug stability, high in bioavailability and gastrointestinal absorption rate and reasonable in compatibility; the preparation process is relatively good, the preparation conditions are easy to realize, and industrialization is facilitated; the optimization of the combination of the preparation process and the product performance is realized.

The invention discloses a ginseng composition beverage capable of promoting gastrointestinal absorption and a preparation method and application thereof, and belongs to the technical field of foods.The ginseng composition beverage capable of promoting gastrointestinal absorption is prepared from ginsenoside extract, phospholipid substances and cyclodextrin; the ginsenoside extract comprises ginsenoside Rg1, ginsenoside Re and ginsenoside Rb1; the ginsenoside extract and the phospholipid substance are combined through a hydrogen bond to form a hydrogen bond conjugate system; the hydrogen bond conjugate system and cyclodextrin form an inclusion compound through an inclusion effect. The functional components ginsenoside Rg1, Re and Rb1 in the ginseng are taken as indexes, the solubility, fat solubility and stability of the three kinds of ginsenoside are improved at the same time at a time, gastrointestinal absorption of the ginseng can be promoted, the ginseng can be better utilized, and the efficacy of the ginseng can be better exerted.

The invention relates to specific polyglycerol derivatives and their further medical uses, namely to dPG / lPG-DTBA and dPG / lPG-cysteamine. These polyglycerol derivatives have a linear or dendritic polyglycerol backbone and carry at least one thiol group covalently bound to the polyglycerol backbone. The claimed medical uses are the use as mucolytic; the use in treating chronic sinusitis, asthma, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease, emphysema, or bronchiectasis; and the use in treating chronic inflammatory bowel diseases, constipation, gastrointestinal malabsorption syndrome, irritable bowel syndrome, steatorrhea or diarrhea.

This invention relates to the field of traditional Chinese medicine preparation technology, specifically to a blood-activating and meridian-clearing traditional Chinese medicine composition with agarwood as the principal ingredient. The composition comprises the following raw materials in parts by weight: 5-15 parts modified agarwood complex, 40-60 parts compound extract powder, 1-3 parts broken-cell-wall scorpion powder, 20-50 parts filler, and 0.5-2 parts lubricant. This invention improves the efficient release of the effective components of agarwood as the principal ingredient by using the modified agarwood complex, ensuring the stability of the core efficacy of agarwood and extending the retention time of its core components. The addition of compound extract powder scientifically combines blood-activating and blood-nourishing herbs, ensuring powerful meridian clearing while replenishing qi and blood, reducing the side effects of long-term medication, and improving patient safety. The broken-cell-wall scorpion powder reduces the risk of sensitization and poisoning, breaking the cell walls of the scorpion to fully release the core analgesic peptides and antithrombotic peptides, thus improving gastrointestinal absorption efficiency.

The present disclosure belongs to the field of biological medicine, and particularly relates to an oral polypeptide composition for improving gastrointestinal absorption of polypeptide drugs; and particularly discloses an oral polypeptide composition, which comprises polypeptide molecules, medium-chain fatty acids and salts thereof, amino acids, and N-(8-(2-hydroxybenzoyl)amino)octanoic acid (NAC) and salts thereof. The oral polypeptide preparation of the present disclosure can effectively improve the blood drug concentration of polypeptides, and improve the bioavailability of oral polypeptides.

The invention relates to application of a gastric retention shape memory composite membrane. The gastric retention shape memory composite membrane is prepared by the following method: (1) mixing a polymer with dichloromethane to obtain a solution 1; (2) preparing a solution 2 by taking water as a solvent, wherein the solution 2 contains hydroxypropyl methyl cellulose and NaHCO3; and (3) mixing the solution 1 and the solution 2, stirring, adding the luteolin phospholipid complex, continuously stirring, and volatilizing dichloromethane and water. The gastro-retention shape memory composite membrane provided by the invention can be used for preparing a medicine for treating gastric cancer, has a good in-vivo expansion effect, has the deformation temperature closer to the temperature of a human body, and can enhance the permeation of luteolin to a biological membrane, improve the gastrointestinal absorption effect of luteolin, reduce stomach discomfort of a patient and improve the bioavailability of the medicine.

The invention discloses a soft capsule for improving an anxiety state as well as a preparation method and application of the soft capsule, and belongs to the technical field of pharmaceutical preparations. Comprising contents and a capsule shell wrapping the contents. The content consists of a compound extract, phospholipid and emotional fish oil. The compound extract is prepared from bupleurum chinense, salvia miltiorrhiza, cape jasmine, angelica sinensis, bighead atractylodes rhizome, poria cocos, dried ginger, mint and liquorice; the capsule shell comprises chitosan, sodium alginate, a rosemary extract microcapsule, vitamin C palmitate, titanium dioxide, pachymaran and the like, and the rosemary extract microcapsule is prepared from a rosemary extract through pachymaran microencapsulation. Through the synergistic effect of all the components, the compatibility of the compound extract and the emotional fish oil is effectively improved, the stability of an oil phase system is improved, the oxidative rancidity risk of the emotional fish oil is reduced, meanwhile, the emotional fish oil is matched with the gastrointestinal absorption characteristics of people with weakness of the spleen and the stomach, and a pharmaceutical preparation choice is provided for conditioning the anxiety state.

The invention relates to a gastric retention shape memory composite membrane. The gastric retention shape memory composite membrane is prepared by the following method: (1) mixing a polymer with dichloromethane to obtain a solution 1; (2) preparing a solution 2 by taking water as a solvent, wherein the solution 2 contains hydroxypropyl methyl cellulose and NaHCO3; and (3) mixing the solution 1 and the solution 2, stirring, adding the luteolin phospholipid complex, continuously stirring, and volatilizing dichloromethane and water. The gastro-retention shape memory composite membrane provided by the invention has a good in-vivo expansion effect, the deformation temperature of the gastro-retention shape memory composite membrane is closer to the temperature of a human body, and the gastro-retention shape memory composite membrane can enhance penetration of luteolin to a biological membrane, improve the gastrointestinal absorption effect of the luteolin, reduce stomach discomfort of a patient and improve the bioavailability of a medicine.

The invention relates to the technical field of milk powder formulas, in particular to novel goat milk infant formula milk powder and a preparation method thereof. Comprising the following raw materials: 40% to 80% of raw goat milk, 6% to 10% of desalted goat whey powder, 1.6% to 2.4% of vegetable oil, 0.4% to 0.8% of lactose, 0.2% to 0.3% of galactooligosaccharide, 0.1% to 0.3% of fructo-oligosaccharide, 0.02% to 0.06% of docosahexaenoic acid, 0.02% to 0.06% of arachidonic acid, 0.01% to 0.04% of bifidobacterium, 0.01% to 0.04% of rhamnose lactic acid bacteria, 0.01% to 0.02% of lactoferrin, 0.01% to 0.03% of L-carnitine, 0.1% to 0.3% of a vitamin premixing bag and 0.1% to 0.3% of a mineral substance premixing bag. According to the present invention, the probiotic powder contains the metabiotics and the sufficient number of the three probiotics and the sufficient number of the two prebiotics, such that the bottleneck problem that the traditional probiotics do not resist the high temperature and the gastric acid and cannot directly reach the human intestinal tract is solved; the composition can directly and rapidly act on human bodies through intestinal barriers, can promote gastrointestinal absorption of infants, and improves immunity of the infants.

The present invention relates to, for oral delivery of biodrugs, a multi-arm polyethylene glycol-KLA peptide conjugate, a PEGylated distearoyl phosphatidylethanolamine-KLA peptide conjugate, a PAMAM dendrimer-KLAL peptide conjugate, and a composition for enhancing absorption, in the gastrointestinal tract, of a biodrug for oral administration containing same as oral absorption enhancers, the conjugates of the present invention reducing cytotoxicity due to the cell permeable properties of a KLA peptide, and maintaining a tight junction modulation function of KLA through effects such as increasing resistance to proteolytic enzymes in the gastrointestinal tract, so as to promote gastrointestinal absorption of biodrugs such as peptides, proteins, polysaccharides, and antibodies when orally administrated, and thus being able to be usefully employed in increasing the bioavailability of a drug.

The invention discloses edible gel for preventing drunkenness as well as a preparation method and application thereof, the gel is stimulated by ethanol in gastrointestinal tracts to trigger crosslinking to form gel, the ethanol is adsorbed, the exposure of the ethanol in the gastrointestinal tracts is reduced, and meanwhile, a formed gel film can effectively isolate direct contact between the ethanol and mucous membranes of the gastrointestinal tracts. Through the combined action of the two aspects, alcohol gastrointestinal absorption is reduced, and the alcohol level in the body after drinking is reduced. The gel shows remarkable ethanol adsorption capacity and capacity of preventing ethanol from penetrating through intestinal tracts in an in-vitro experiment; a mouse drunkenness model verifies that drunkenness and death caused by drinking can be reduced through pretreatment, the drunkenness tolerance time is remarkably prolonged, movement coordination disorder caused by alcohol can be improved, and the blood ethanol concentration of a mouse after drinking is effectively reduced. The gel can effectively reduce gastrointestinal tract absorption of ethanol and alleviate alcoholic liver injury, and provides a brand new technical path for development of related preparations for dispelling the effects of alcohol and protecting liver.

The application relates to a preparation method of a gastric-retention shape memory composite film, which comprises the following steps: (1) mixing a polymer with dichloromethane to obtain solution 1; (2) preparing solution 2 with water as a solvent, wherein the solution 2 contains hydroxypropyl methyl cellulose and NaHCO3; (3) mixing the solution 1 and the solution 2, stirring, adding a luteolin phospholipid complex, continuing to stir, and volatilizing dichloromethane and water. The shape memory film provided by the application has good unfolding effect in the body, the deformation temperature is closer to the human body temperature, the permeation of luteolin to the biological membrane can be strengthened, the gastrointestinal absorption effect of luteolin is improved, the stomach discomfort of patients is reduced, and the bioavailability of the drug is improved.

The invention relates to the technical field of sports nutritious food, and discloses cashew nut and sea cucumber peptide sports recovery powder and method, the cashew nut and sea cucumber peptide sports recovery powder comprises the following components by mass: 40%-55% of a composite peptide composition, 25%-35% of a rapid energy supply matrix, 5%-10% of an anti-inflammatory active component, and 10%-15% of a synergistic auxiliary agent, the composite peptide composition is prepared by compounding cashew nut peptide and sea cucumber peptide according to a mass ratio of (4-6): (3-5), the molecular weight distribution of the cashew nut peptide is 200-800Da, the purity of the cashew nut peptide is greater than or equal to 92%, the molecular weight distribution of the sea cucumber peptide is 300-1000Da, the purity of the sea cucumber peptide is greater than or equal to 90%, the rapid energy supply matrix is formed by compounding maltodextrin and fructo-oligosaccharide according to the mass ratio of (3-4): 1, and the anti-inflammatory active component comprises curcumin microcapsules and resveratrol. Through the specific compounding design of the cashew nut peptide and the sea cucumber peptide and in combination with precise molecular weight control, advantage complementation of amino acid composition is realized, and the gastrointestinal tract absorption efficiency of nutritional ingredients is remarkably improved in cooperation with a targeted slow release technology of curcumin microcapsules.